【摘要】 目的:探究重性抑郁障碍患者肠道菌群特征与艾司西酞普兰治疗效果的关联分析。方法:选取91例重性抑郁障碍患者为研究对象，根据药物治疗效果分为应答组(n=52)和非应答组(n=39),选取同期39名健康对照纳入健康对照组，采用16S rDNA测序方法检测肠道菌群，采用Logistic回归分析评价重性抑郁障碍患者肠道菌群特征与艾司西酞普兰治疗效果间的关系。结果:3组患者肠道菌群α多样性和β多样性存在明显差异(P<0.05)。在属水平上，应答组患者的肠道菌群中以毛螺菌科、拟杆菌属、阿克曼氏菌属、双歧杆菌属和乳杆菌属占主要优势，而非应答组患者肠道菌群中以放线菌属、伊格尔兹氏菌属、安德克氏菌属、克里斯滕森菌属占主要优势。多因素Logistic分析显示，Chao1指数(OR=1.026,P=0.002)、Shannon指数(OR=3.190,P=0.014)为影响重性抑郁障碍患者艾司西酞普兰治疗效果的独立危险因素。结论:重性抑郁障碍患者肠道菌群α、β多样性与艾司西酞普兰治疗效果有显著的相关性。更多还原

【Abstract】 Objective: To explore the relationship between intestinal flora characteristics and treatment effect of escitalopram in patients with major depressive disorder. Method:A total of 91 patients with major depressive disorder were selected as study objects, and divided into the response group(n=52) and the non-response group(n=39) according to drug treatment effect.During the same period, 39 healthy control were selected, and intestinal flora was detected by 16S rDNA sequencing method.Logistic regression analysis was used to evaluate the relationship between intestinal flora characteristics and treatment effect of escitalopram in patients with major depressive disorder. Results:There were significant differences in α and β diversity of intestinal flora among the three groups(P<0.05).At the genus level, the intestinal flora of patients in the response group were mainly dominated by Spirillaceae, Bacteroides, Ackermania, Bifidobacterium and Lactobacillus, while those in the non-response group were mainly dominated by Actinomyces, Iglesia, Anderkeria and Christensenia.Multivariate Logistic analysis showed that Chao1 index(OR=1.026,P=0.002) and Shannon index(OR=3.190,P=0.014) were independent risk factors affecting the treatment effect of escitalopram in patients with major depressive disorder. Conclusion:The α and β diversity of intestinal flora in patients with major depressive disorder are significantly correlated with the therapeutic effect of escitalopram.更多还原